新型靶向疗法：类风湿关节炎的未来？以马夫珠单抗和塔巴珠单抗为例。 - Suppr | 超能文献

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.

作者信息

Combe Bernard, van Vollenhoven Ronald

出版信息

Ann Rheum Dis. 2013 Sep 1;72(9):1433-5. doi: 10.1136/annrheumdis-2013-203261. Epub 2013 Apr 26.

DOI:10.1136/annrheumdis-2013-203261

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.新型靶向疗法：类风湿关节炎的未来？以马夫珠单抗和塔巴珠单抗为例。

Ann Rheum Dis. 2013 Sep 1;72(9):1433-5. doi: 10.1136/annrheumdis-2013-203261. Epub 2013 Apr 26.

2

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.巴鲁单抗，一种抗 BAFF 单克隆抗体，用于治疗对 TNF 抑制剂应答不足的活动性类风湿关节炎患者。

Ann Rheum Dis. 2013 Sep 1;72(9):1461-8. doi: 10.1136/annrheumdis-2012-202775. Epub 2012 Dec 25.

3

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.对于对甲氨蝶呤反应不足且未接受过生物治疗的类风湿关节炎患者，使用他巴鲁单抗的一项II期随机安慰剂对照试验。

Arthritis Rheum. 2013 Apr;65(4):880-9. doi: 10.1002/art.37820.

4

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.皮下注射塔巴鲁单抗治疗对甲氨蝶呤应答不足的活动性类风湿关节炎患者的 2 期剂量范围研究。

Ann Rheum Dis. 2013 Sep 1;72(9):1453-60. doi: 10.1136/annrheumdis-2012-202864. Epub 2013 Apr 18.

5

Adalimumab for rheumatoid arthritis?阿达木单抗用于治疗类风湿关节炎？

Am Fam Physician. 2006 Feb 1;73(3):435-6.

6

[Treatment of rheumatoid arthritis with adalimumab. Results from a Cochrane review].[阿达木单抗治疗类风湿关节炎。Cochrane系统评价结果]

Ugeskr Laeger. 2006 Aug 28;168(35):2899-903.

7

Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach.生物制剂治疗类风湿关节炎的疗效：间接比较法。

Pharmacotherapy. 2011 Jan;31(1):39-51. doi: 10.1592/phco.31.1.39.

8

New drugs for rheumatoid arthritis.治疗类风湿性关节炎的新药。

N Engl J Med. 2004 Aug 26;351(9):937-8. doi: 10.1056/NEJM200408263510922.

9

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.巴利昔单抗，一种抗 B 细胞激活因子单克隆抗体，治疗对甲氨蝶呤应答不足的类风湿关节炎患者的疗效和安全性：来自一项 III 期多中心、随机、双盲研究的结果。

Ann Rheum Dis. 2015 Aug;74(8):1567-70. doi: 10.1136/annrheumdis-2014-207090. Epub 2015 Apr 14.

10

Rheumatoid arthritis.类风湿关节炎

N Engl J Med. 2004 Sep 23;351(13):1360-1; author reply 1360-1. doi: 10.1056/NEJM200409233511322.

引用本文的文献

1

ROS-Responsive Berberine Polymeric Micelles Effectively Suppressed the Inflammation of Rheumatoid Arthritis by Targeting Mitochondria.活性氧应答性黄连素聚合物胶束通过靶向线粒体有效抑制类风湿性关节炎的炎症。

Nanomicro Lett. 2020 Mar 20;12(1):76. doi: 10.1007/s40820-020-0410-x.

2

Patients' conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis.患者对自身在慢性炎症性关节炎生物治疗良好反应中所起作用的认知。

Patient Prefer Adherence. 2017 Jun 26;11:1057-1067. doi: 10.2147/PPA.S131239. eCollection 2017.

3

Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.单剂量他巴鲁单抗在类风湿性关节炎或系统性红斑狼疮患者中的药代动力学及安全性

Br J Clin Pharmacol. 2016 May;81(5):908-17. doi: 10.1111/bcp.12860. Epub 2016 Feb 25.